These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27736689)

  • 1. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.
    Mischoulon D; Hylek L; Yeung AS; Clain AJ; Baer L; Cusin C; Ionescu DF; Alpert JE; Soskin DP; Fava M
    J Affect Disord; 2017 Jan; 208():6-14. PubMed ID: 27736689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
    Mischoulon D; Witte J; Levy M; Papakostas GI; Pet LR; Hsieh WH; Pencina MJ; Ward S; Pollack MH; Fava M
    J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.
    Ravindran AV; Kennedy SH; O'Donovan MC; Fallu A; Camacho F; Binder CE
    J Clin Psychiatry; 2008 Jan; 69(1):87-94. PubMed ID: 18312042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study.
    Han C; Wang SM; Kwak KP; Won WY; Lee H; Chang CM; Tang TC; Pae CU
    J Psychiatr Res; 2015; 66-67():84-94. PubMed ID: 26013203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.
    Fava M; Memisoglu A; Thase ME; Bodkin JA; Trivedi MH; de Somer M; Du Y; Leigh-Pemberton R; DiPetrillo L; Silverman B; Ehrich E
    Am J Psychiatry; 2016 May; 173(5):499-508. PubMed ID: 26869247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder.
    Plank JR; Glover SC; Moloney BD; Hoeh NR; Sundram F; Sumner RL; Muthukumaraswamy S; Lin JC
    Trials; 2022 Sep; 23(1):822. PubMed ID: 36175917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressants effects of Rhodiola capsule combined with sertraline for major depressive disorder: A randomized double-blind placebo-controlled clinical trial.
    Gao L; Wu C; Liao Y; Wang J
    J Affect Disord; 2020 Mar; 265():99-103. PubMed ID: 32090788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
    Weisler RH; Khan A; Trivedi MH; Yang H; Eudicone JM; Pikalov A; Tran QV; Berman RM; Carlson BX
    J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sertraline Versus Placebo in Patients with Major Depressive Disorder Undergoing Hemodialysis: A Randomized, Controlled Feasibility Trial.
    Friedli K; Guirguis A; Almond M; Day C; Chilcot J; Da Silva-Gane M; Davenport A; Fineberg NA; Spencer B; Wellsted D; Farrington K
    Clin J Am Soc Nephrol; 2017 Feb; 12(2):280-286. PubMed ID: 28126706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder.
    Kamijima K; Kimura M; Kuwahara K; Kitayama Y; Tadori Y
    Psychiatry Clin Neurosci; 2018 Aug; 72(8):591-601. PubMed ID: 29660207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial.
    Mao JJ; Xie SX; Zee J; Soeller I; Li QS; Rockwell K; Amsterdam JD
    Phytomedicine; 2015 Mar; 22(3):394-9. PubMed ID: 25837277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
    Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
    J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.
    Abbasi SH; Hosseini F; Modabbernia A; Ashrafi M; Akhondzadeh S
    J Affect Disord; 2012 Dec; 141(2-3):308-14. PubMed ID: 22516310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.